{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6","upperLimit":"18","value":"9.7"}]}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6","upperLimit":"17","value":"10.2"}]}],"title":"Day 16"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"The steady state plasma concentration (Css) of trametinib with concomitant dabrafenib administration was assessed at Day 15 and Day 16. At steady state the amount of drug administered (in a given time period) is equal to the amount of drug eliminated.","dispersionType":"Full Range","groups":[{"description":"Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).","id":"OG000","title":"Part A: Dabrafenib 75 mg + Trametinib 2 mg"}],"paramType":"MEDIAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Day 15 and Day 16","title":"Part A: Steady State Concentration of Trametinib With Concomitant Administration of Dabrafenib","type":"SECONDARY","unitOfMeasure":"ng/mL"}